Sustainability Investors Products Research & Development Company Contact
Sustainability
ESG Environment Social
Investors
Reasons to invest Share information News Reports Corporate governance Stock exchange notices
Products
Salmon protein hydrolysate Salmon oil Calcium bone powder Collagen peptides European webshops
Research & Development
Our research All research programs Studies Clinical Trial Unit
Company
About us Our technology Operations Management Board of directors Awards
Contact
Sales Investor relations Factories Management
Type and search

All notices

FOURTH QUARTER 2021 FINANCIAL REPORT

04.02.2022

MANDATORY NOTIFICATION OF TRADE

22.12.2021

COMPLETED EXTRAORDINARY GENERAL MEETING

03.12.2021

HBC INGREDIENTS SUCCESSFULLY RECEIVE NEW DIETARY INGREDIENT (NDI) STATUS FROM THE US FDA

02.12.2021

MANDATORY NOTIFICATION OF TRADE

18.11.2021

NOTICE OF EXTRAORDINARY GENERAL MEETING

08.11.2021

NEW POTENTIAL PHARMACEUTICAL DRUG LEADS BY HBC

05.11.2021

THIRD QUARTER 2021 FINANCIAL REPORT

05.11.2021

THE BOARD OF DIRECTORS PROPOSES TO ELECT AMY NOVOGRATZ AS NEW DIRECTOR

04.11.2021

AQUA SPARK AS NEW STRATEGIC INVESTOR IN HBC

04.11.2021

Previous
1
2
3 4 5
...
30
Next
Sustainability
ESG Environment Social
Investors
Reasons to invest Share information News Reports Corporate governance Stock exchange notices
Products
Salmon protein hydrolysate Salmon oil Calcium bone powder Collagen peptides European webshops
Research & Development
Our research All research programs Studies Clinical Trial Unit
Company
About us Our technology Operations Management Board of directors Awards
Contact
Sales Investor relations Factories Management

Copyright 2021 Hofseth BioCare ASA
Privacy cookies